The most common PPO criteria were osmotic laxatives for chronic constipation (18%), SGLT-2 inhibitors in heart failure (13.2%), mineralocorticoid receptor antagonists in heart failure (7.8%), and statin therapy with a history of cardiovascular disease (6%). The gene discussed is SLC5A2; the disease is Chronic constipation.